By controlling appetite and improving insulin sensitivity, the therapy supports several beneficial outcomes: Reduced portion sizes and improved satiety Lower caloric intake without excessive hunger Improved glycaemic control in patients with insulin resistance or metabolic syndrome Favourable body-composition changes , with a higher ratio of fat loss to lean mass loss Improved cardiometabolic markers , including cholesterol and blood pressure Clinical studies have shown that individuals on GLP-1 receptor agonist therapy can experience significant reductions in body weight over time when combined with dietary adjustments and physical activity
doi: 10.1016/j.livsci.2012.08.008 112
Frias JP, Nauck MA, Van J, Benson C, Bray R, Cui X, Milicevic Z, Urva S, Haupt A, Robins DA
To further elucidate the role of these genes in T1D pathology, future studies should utilize islets from patients harboring these variants or genetically engineered stem cell-derived islets and treat them with various stressors to delineate unique responses